# ENHANCED CCNG1 EXPRESSION IN TUMORS MAY PREDICT CLINICAL BENEFIT FROM DELTAREX-G, A TUMOR TARGETED RETROVECTOR ENCODING A CCNG1 INHIBITOR GENE

## Abstract #1147

Erlinda M. Gordon<sup>1,2</sup>, Nadezhda Omelchenko<sup>1</sup>, Caroline Eid<sup>3</sup>, Samantha Jeffrey<sup>4</sup>, Elan Younes<sup>1</sup>, Neal Chawla<sup>5</sup>, ZhannaShekhovtsova<sup>6</sup>, Aleksei Omelchenko<sup>1</sup>, Kushal Suryamohan<sup>6</sup>, Don Brigham<sup>2</sup>, Michael Morse<sup>7</sup>, Sant P. Chawla<sup>1</sup> <sup>1</sup>Cancer Center of Southern California/Sarcoma Oncology Research Center, Santa Monica, CA, <sup>3</sup>University of Southern California, Los Angeles, CA, <sup>4</sup>University of Southern California, Los Angeles, CA, <sup>4</sup>University of Southern California, Los Angeles, CA, <sup>5</sup>City of Hope, Duarte, CA, <sup>6</sup>Boston Gene, Inc., Waltham, MA, <sup>7</sup>Duke University Medical Center, Durham, NC

### Abstract

**Background:** Metastatic cancer is associated with an invariably fatal outcome. Therefore, innovative therapies are urgently needed. Although expanded access for DeltaRex-G, a tumor targeted retrovector encoding a CCNG1 inhibitor gene, is ongoing for an intermediate-size (n=up to 40) population of advanced sarcoma and pancreatic cancer, more data is needed to identify patients who are likely to benefit from DeltaRex-G gene therapy. In this study, we retrospectively analyzed CCNG1 expression in archived tumors of patients who were previously treated with DeltaRex-G and who are active candidates for DeltaRex-G therapy.

**Methods:** Archived formalin-fixed paraffin-embedded (FFPE) tumor specimens (n=58) from patients with solid malignancies who are actively followed at the Cancer Center of Southern California were collected, processed, and subjected to RNA sequencing. Briefly, RNA-seq libraries were sequenced to generate 50 million reads that were aligned using Kallisto v0.42.4 to GENCODE v23 transcripts with default parameters. Only proteincoding, IGH/K/L-, and TCR-related transcripts were retained for downstream processing, resulting in 20,062 protein-coding genes. Gene expression was quantified as transcripts per million (TPM) and log2-transformed. A gene expression level is presented as low, medium or high depending on the expression level of a such gene in patients of the reference cohort. Low = <17%; Medium = 17%-83%; High = >83%.

**Results:** Thirty-two male and 26 female subjects, ages ranging from 16 to 86 years were studied. Forty-nine (84.4%) patients had sarcoma, 3 (5.2%) had urothelial carcinoma, 2 (3.5%) had breast carcinoma, 2 (3.5%) had pancreatic cancer, 1 (1.7%) had Sertoli cell tumor, 1 (1.7%) had adenocarcinoma of appendix. Eleven (19%) tumors showed high CCNG1 expression, 44 (76%) tumors had medium expression, and 3 (5.2%) tumors had low CCNG1 expression. Of note, in DeltaRex-G treated patients, the tumor of one 14year survivor with metastatic pancreatic adenocarcinoma in sustained remission had 24 % CCNG1 expression, one 3-year survivor with metastatic chondrosarcoma metastatic to lung with stable disease had 74% CCNG1 expression, one 2-year survivor with early stage HR+ HER2+ breast cancer in remission had 23% CCNG1 expression, and one 2-year survivor with early stage triple negative breast cancer in remission had 74% CCNG1 expression.

**Conclusion:** Taken together, these data indicate that (1) Medium to high CCNG1 expression was found in 95% of tumors studied, (2) Patients with medium CCNG1 expression who received DeltaRex-G had clinical benefit and are alive in sustained remission or with stable disease 2-14 years from DeltaRex-G treatment initiation, and (3) Prospective studies are warranted to correlate CCNG1 expression level and response to DeltaRex-G therapy.


center

CALIFORNIA

### **Contact:**

Erlinda M. Gordon, MD Cancer Center of Southern California, Santa Monica, CA USA egordon@sarcomaoncology.com Phone: (312)522-9999















**References:** 1. Gordon EM and Hall FL (2023). Front. Mol. Med. 3:1125928. doi: 10.3389/fmmed.2023.1125928 2023. 2. Chawla SP, Wong S, Quon D, Moradkhani A, Chua VS, Brigham DA, et al. (2022) Front. Mol. Med. 2: 1092286, 2022. doi: 10.3389/fmmed.2022.1092286 3. Morse MA, Chawla SP, Wong T, Bruckner HW, Hall FL, Gordon EM. (2021). Molecular Clinicial Oncology, 15: 186. DOI: 10.3892/mco.2021.2348 4. Ravicz J, Szeto C, Reddy S, Chawla SP, Morse MA, Hall FL, Gordon EM. (2021). J. Cancer Research and Cellular Therapeutics, 5(4); Doi:10.31579/2640-1053/090 5. Chawla SP, Bruckner H, Morse MA, Assudani N, Hall FL, Gordon EM. Molecular Therapy Oncolytics 12: 56-67, 2019.